___

Fernandez H, Chabbert-Buffet N, Koskas M, Nazac A. Epidemiological data for uterine fibroids in France in 2010-2012 in medical center - analysis from the French DRG-based information system (PMSI). J Gynecol Obstet Biol Reprod (Paris). 2014;43(8):616-28.

Parker WH. Uterine myomas: management. Fertil Steril 2007;88(2):255-71.

American College of Obstetricians and Gynecologists. Alternatives to hysterectomy in the management of leiomyomas. ACOG Practice Bulletin No. 96. Obstet Gynecol. 2008;112(2 pt 1):387-400.

Marret H, Fritel X, Ouldamer L, Bendifallah S, Brun JL, De Jesus I, Derrien J, Giraudet G, Kahn V, Koskas M, Legendre G, Lucot JP, Niro J, Panel P, Pelage JP, Fernandez H; CNGOF (French College of Gynecology and Obstetrics). Therapeutic management of uterine fibroid tumors: updated French guidelines. Eur J Obstet Gynecol Reprod Biol. 2012;165:156-64.

Pérez-López FR, Ornat L, Ceausu I, Depypere H, Erel CT, Lambrinoudaki I, Schenck-Gustafsson K, Simoncini T, Tremollieres F, Rees M. EMAS position statement: management of uterine fibroids. Maturitas. 2014;79(1):106-16.

Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293-8.

Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women's Health Study: II. Outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic pain. Obstet Gynecol. 1994;83(4):566-72.

Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2006;(2):CD003855.

Qin J, Yang T, Kong F, Zhou Q. Oral contraceptive use and uterine leiomyoma risk: A meta-analysis based on cohort and case-control studies. Arch Gynecol Obstet. 2013;288(1):139-48.

Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams- Campbell LL, Rosenberg L. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol. 2004;159(2):113-23.

Venkatachalam S, Bagratee JS, Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. J Obstet Gynaecol. 2004; 24(7):798-800.

Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril. 2003;79(5):1194-8.

Murat Naki M, Tekcan C, Ozcan N, Cebi M. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes. Fertil Steril. 2010;94(1):371-4.

Kriplani A, Awasthi D, Kulshrestha V, Agarwal N. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int J Gynaecol Obstet. 2012;116(1):35-8.

Lähteenmäki P, Haukkamaa M, Puolakka J, Riikonen U, Sainio S, Suvisaari J, Nilsson CG. Open randomised study of use of levonorgestrel releasing intrauterine 1998;316(7138):1122-6. as alternative to hysterectomy. BMJ.

Gutmann JN, Corson SL. GnRH agonist therapy before myomectomy or hysterectomy. J Minim Invasive Gynecol. 2005;12(6):529-37.

Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2000;(2):CD000547.

Nieman LK, Blocker W, Nansel T, Mahoney S, Reynolds J, Blithe D, Wesley R, Armstrong A. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril. 2011;95(2):767-72.e1-2.

Melli MS, Farzadi L, Madarek EO. Comparison of the effect of gonadotropin- releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on uterine myoma regression. Saudi Med J. 2007;28(3):445-50.

Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, Nouri K, Selvaggi L, Sodowski K, Bestel E, Terrill P, Osterloh I, Loumaye E; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421-32.

Brahma PK, Martel KM, Christman GM. Future directions in myoma research. Obstet Gynecol Clin North Am. 2006;33(1):199-224, xiii.

Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol. 2005;12(3):227-33.

Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004;103(6):1331-6.

Palomba S, Sammartino A, Di Carlo C, Affinito P, Zullo F, Nappi C. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril. 2001;76(1):38-43.

Premkumar A, Venzon DJ, Avila N, Johnson DV, Remaley AT, Forman MR, Eng-Wong J, Zujewski J, Stratton P.. Gynecologic and hormonal effects of raloxifene in premenopausal women. Fertil Steril. 2007;88(6):1637-44.

Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, Frank V, Schmidt EH. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010;93(1):192-8.

Mäkäräinen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol. 1986;93(9):974-8.

Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma- induced menorrhagia. Obstet Gynecol. 1986;68(1):10-2.

Vessey MP, Villard-Mackintosh L, McPherson K, Coulter A, Yeates D. The epidemiology of hysterectomy: findings in a large cohort study. Br J Obstet Gynaecol. 1992;99(5):402-7.

Management of Uterine Fibroids. Summary, Evidence Report/Technology Assessment: Number 34. AHRQ Publication No. 01-E051, January 2001. Agency for Healthcare Research and Quality, Rockville.

Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2004; 104(2):393-406.

Goldfarb HA. Myoma coagulation (myolysis). Obstet Gynecol Clin North Am. 2000;27(2):421-30.

Arcangeli S, Pasquarette MM. Gravid uterine rupture after myolysis. Obstet Gynecol. 1997;89(5 pt 2):857.

Hald K, Langebrekke A, Klİw NE, Noreng HJ, Berge AB, Istre O. Laparoscopic occlusion of uterine vessels for the treatment of symptomatic fibroids: Initial experience and comparison to uterine artery embolization. Am J Obstet Gynecol. 2004;190(1):37-43.

Gupta JK, Sinha AS, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic 2006;(1):CD005073. fibroids. Cochrane Database Syst Rev

Vilos GA, Vilos EC, Romano W, Abu-Rafea B. Temporary uterine artery occlusion for treatment of menorrhagia and uterine fibroids using an incisionless Doppler-guided transvaginal clamp: case report. Hum Reprod. 2006;21(1):269-71.

Marret H, Cottier JP, Alonso AM, Giraudeau B, Body G, Herbreteau D. Predictive factors for fibroids recurrence after uterine artery embolisation. BJOG. 2005;112(4):461-5.

Edwards RD, Moss JG, Lumsden MA, Wu O, Murray LS, Twaddle S, Murray GD; Committee of the Randomized Trial of Embolization versus Surgical Treatment for Fibroids. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med. 2007;356(4):360-70.

Stewart EA, Gedroyc WM, Tempany CM, Quade BJ, Inbar Y, Ehrenstein T, Shushan A, Hindley JT, Goldin RD, David M, Sklair M, Rabinovici J. Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique. Am J Obstet Gynecol. 2003;189(1):48- 54.